NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Metastatic Breast Cancer

CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Home
/
update
/
details

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

NextEdge Admin

31 Jan 2025

3 min 8 sec

Quibim, a pioneering healthtech company specializing in imaging biomarkers for precision medicine, has secured $50 million in Series A financing. The investment was led by Asabys (Sabadell Asabys II) and Buenavista Equity Partners (BHG I fund), alongside new investors UI Investissements and GoHub Ventures. Existing investors, including Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund), Tony Fadell’s Build Collective, and Dr. Jonathan Milner, also participated.

Quibim has seen a 168% quarter-on-quarter increase in patient analyses, driven by regulatory approvals and strategic global partnerships. The company’s AI-powered imaging technology extracts insights from MRI, CT, and PET scans, aiding in disease characterization and outcome prediction across oncology, neurology, immunology, and metabolic disorders. This work contributes to the development of human digital twins—dynamic models that enhance patient stratification, improve drug development, and enable virtual treatment testing.

With over 170 global installations, including at Mass General Brigham and Stanford, Quibim’s technology integrates imaging, AI, and computing to advance healthcare. Its AI models are FDA-cleared and CE-marked, with solutions such as:

QP-Prostate®: AI-powered lesion detection for prostate cancer.
QP-Brain®: Quantification of early-stage neurological diseases.
QP-Liver®: MR-based assessment of diffuse liver diseases.
QP-Insights®: A platform managing clinical trial imaging data, supporting Europe’s Beating Cancer Plan.

Recent milestones include a global partnership with Philips to integrate Quibim’s AI into MR scanners and collaborations with pharmaceutical leaders like Merck KGaA and Novartis. Now, with its expanded U.S. presence, Quibim aims to help healthcare providers and pharmaceutical companies process unprecedented amounts of imaging data.

“Asabys is thrilled to support Quibim in revolutionizing imaging diagnostics,” said Guillem Masferrer, Partner at Asabys. “Their AI-driven imaging biomarker technology addresses critical unmet needs.”

Tony Fadell, Build Collective Principal and Nest Founder, added, “Quibim’s AI-enabled insights are already helping doctors detect diseases like cancer early and measure treatment response. Their impact on precision medicine is profound.”

Related Tags

Quibim

AI-Powered Imaging

Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Top Reviews

No reviews yet